Please assess the completion status of the following clinical trial:

Trial Title: Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria -~1. Between the ages of greater or equal to (≥) 6 months and less than (\<) 18 years of age~2. Must have histologically proven B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoblastic lymphoma with marrow involvement~3. All participants (both ALL and participants with lymphoblastic lymphoma) must have M2 or M3 bone marrow classification~4. Disease status: a) Participants must have relapsed or refractory disease b) In the event of relapse after prior allogeneic hematopoietic stem cell transplant (HSCT), participants must be at least 3 months post-transplant and have no evidence of active graft-vs-host disease, and must have been off immunosuppression for at least 4 weeks, c) Must have resolution of the acute toxic effects to less than or equal to (≤) Grade 2 from prior chemotherapy before entry, in the opinion of the investigator~5. Participants with the following central nervous system (CNS) 1 or 2 status are eligible only in the absence of neurologic symptoms~6. Female participants of childbearing potential and post-pubertal male participants must use an approved method of contraception for the study.~Exclusion Criteria~1. Concurrent enrollment in another clinical study for cancer treatment, unless the subject is in the follow-up period from a previous study.~2. Isolated testicular or CNS ALL~3. Participants with mixed-lineage leukemia (MLL) gene rearrangement~4. Inadequate Hepatic function~5. Inadequate Renal function~6. Radiologically-detected CNS lymphoma~7. Participants with clear laboratory or clinical evidence of disseminated intravascular coagulation (DIC)~8. Hyperleukocytosis or rapidly progressive disease that would compromise ability to complete study therapy~9. QT interval corrected using Fridericia's formula (QTcF) greater than or equal to a Grade 2, confirmed by 2 additional seperate electrocardiographs (ECG's) within 28 days prior to starting study drug. The initial screening ECG need not be repeated for confirmation if the QTcF interval is \<481 milliseconds.~10. Pregnant or breast-feeding females~11. Prior treatment with CAT-3888 (BL22), moxetumomab pasudotox, or any pseudomonas-exotoxin-containing compound~12. Prior treatment with any anticancer biologic therapy within 2 weeks prior to starting study drug, including but not limited to therapeutic monoclonal antibodies or antibody-drug conjugates~13. Systemic chemotherapy ≤ 2 weeks (6 weeks for nitrosoureas) and radiation therapy ≤ 3 weeks prior to starting study drug~14. Clinically significant ophthalmologic findings (evidence of retinal damage or injury) during the screening~15. Presence of a second invasive malignancy~16. Uncontrolled pulmonary infection, presence of pulmonary edema~17. Serum albumin \< 2 gram per deciliter (g/dL). Albumin infusions for correction of hypoalbuminemia are allowed, but cannot have administered within 7 days prior to start of study drug~18. Radioimmunotherapy within 2 years prior to study start of study drug~19. Participants with prior history of thrombotic microangiopathy or hemolytic uremic syndrome (HUS)~20. T-cell ALL or T-cell lymphoblastic lymphoma~21. Participants currently receiving high-dose estrogen therapy defined as \>0.625 milligram per day (mg/day) of an estrogen compound or within 2 weeks prior to starting study drug.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Moxetumomab Pasudotox 40 mcg/kg (Type: EXPERIMENTAL): Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).